Literature DB >> 24403485

Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma.

Tadej Strojnik1, Tomaz Smigoc, Tamara T Lah.   

Abstract

AIM: To determine any correlation between inflammation parameters in blood glioma patients, with some of the established glioma biomarkers and to evaluate the possible prognostic impact of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for patient survival. PATIENTS AND METHODS: This retrospective study evaluated ESR values in 94 patients and measured CRP values prior to the excision of primary glioma in 165 patients. Overall survival probabilities were determined separately for all patients with glioma in low-grade glioma (LGG), high-grade (HGG) and in glioblastoma multiforme (GBM) using the Kaplan-Meier log-rank test. The correlation between blood ESR and CRP values and between immunohistochemical (IHC) assessment of cluster of differentiation-68 (CD68), cathepsin B and nestin were evaluated.
RESULTS: An ESR above 15 mm/h was significant for poor survival prognosis for patients overall (p<0.001) and in the HGG (p<0.01) and GBM (p<0.04) subgroups. A serum CRP level above 5 mg/l was also identified as prognostic in patients overall (p<0.01), and in the HGG (p=0.02) and GBM (p=0.04) subgroups.
CONCLUSION: Correlations of ESR and serum levels of CRP have been revealed with prognostic tissue biomarkers i.e. cathepsin B, nestin, CD68. Moreover, preoperative measurement of both parameters could be used for survival prognosis in patients with glioma.

Entities:  

Keywords:  C-reactive protein; Cathepsin B; erythrocyte sedimentation rate; glioblastoma; nestin; prognosis; serum biomarkers

Mesh:

Substances:

Year:  2014        PMID: 24403485

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Overexpression of HLA-DR is associated with prognosis of glioma patients.

Authors:  Jinfu Diao; Tianbao Xia; Hongwei Zhao; Jialin Liu; Bin Li; Zhiwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth.

Authors:  Huan Dang; Ji Wang; Jiang-Xue Cheng; Peng-Yuan Wang; Ying Wang; Li-Fei Cheng; Caigan Du; Xiao-Juan Wang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients.

Authors:  Adomas Bunevicius; Andrius Radziunas; Sarunas Tamasauskas; Arimantas Tamasauskas; Edwards R Laws; Giorgio Iervasi; Robertas Bunevicius; Vytenis Deltuva
Journal:  J Neurooncol       Date:  2018-02-19       Impact factor: 4.130

4.  Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma.

Authors:  Faruk Tas; Kayhan Erturk
Journal:  Mol Clin Oncol       Date:  2017-10-04

5.  Inflammation and chemerin in colorectal cancer.

Authors:  Serpil Erdogan; Fatma Meric Yilmaz; Ozan Yazici; Ahmet Yozgat; Sevilay Sezer; Nuriye Ozdemir; Sema Uysal; Tugrul Purnak; Mehmet Ali Sendur; Ersan Ozaslan
Journal:  Tumour Biol       Date:  2015-12-01

6.  Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.

Authors:  Thomas Cash; Elizabeth McIlvaine; Mark D Krailo; Stephen L Lessnick; Elizabeth R Lawlor; Nadia Laack; Joel Sorger; Neyssa Marina; Holcombe E Grier; Linda Granowetter; Richard B Womer; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2016-06-14       Impact factor: 3.167

7.  Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.

Authors:  Erkan Topkan; Ugur Selek; Yurday Ozdemir; Berna A Yildirim; Ozan C Guler; Fuat Ciner; Huseyin Mertsoylu; Kadir Tufan
Journal:  J Neurooncol       Date:  2018-04-25       Impact factor: 4.130

8.  A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank.

Authors:  David J Cote; Jordan H Creed; Claudine M Samanic; Travis A Gerke; Meir J Stampfer; Stephanie A Smith-Warner; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2021-09-24       Impact factor: 2.984

9.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.